EPISODE · Jan 28, 2022 · 11 MIN
MPR Weekly Dose 105 - Antibody Therapies Restricted; Veklury Greenlit for Outpatients; Parsaclisib Indication Withdrawn; Pepaxto Withdrawal Reconsidered; Kimmtrak Approved
from MPR Weekly Dose
Use of monoclonal antibodies restricted due to Omicron; Veklury given the go-ahead as an outpatient treatment; New data produces a reconsideration for Pepaxto withdrawal; And there's a new treatment approval for unresectable or metastatic uveal melanoma.
Embed this episode
Ready to play
MPR Weekly Dose 105 - Antibody Therapies Restricted; Veklury Greenlit for Outpatients; Parsaclisib Indication Withdrawn; Pepaxto Withdrawal Reconsidered; Kimmtrak Approved
0:00
11:23
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MPR Weekly Dose?
This episode is 11 minutes long.
When was this MPR Weekly Dose episode published?
This episode was published on January 28, 2022.
Can I download this MPR Weekly Dose episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!